Vectus Biosystems
- Short interest
- <0.01%
- as of 10 Nov 2025
- Reported shorts
- 1.1K
- Shares on issue
- 53.333M
Vectus Biosystems (VBS) Short Interest
Vectus Biosystems (ASX:VBS) had <0.01% of shares reported as short positions as of 10 Nov 2025, representing 1,054 shares. Vectus Biosystems operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Vectus Biosystems
Vectus Biosystems is a medical research and development company focused on developing therapies for fibrosis and hypertension. Their lead drug candidate, VB0004, is undergoing Phase I human trials as an anti-fibrotic treatment. The company intends to remain a research and development entity, licensing its current and future technologies.
Company profile →Vectus Biosystems (ASX:VBS) has <0.01% of its shares on issue reported as short positions as of 10 Nov 2025, or about 1,054 shares. VBS is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 43, 2026.
Strategy fit
How each stock picker strategy reads VBS today
- Zanger BreakoutWatchScore 28rank 1310 of 1877
- CAN SLIMWatchScore 28rank 818 of 1547
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 15rank 1028 of 1664
Prices to 27 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
VBS fundamentals
In the year to 30 Jun 2026, Vectus Biosystems (ASX:VBS) recorded revenue of A$7.4K and net profit after tax of A$1.6M. A year earlier it recorded revenue of A$18.8K and a net loss after tax of A$1.8M. Year-on-year growth: revenue −60.4% (FY). Net margin 20,977.8% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest VBS news
All news- Results of 2026 AGM
asx · 27 Oct 2026
- 2026 AGM Presentations
asx · 27 Oct 2026
- Vectus Biosystems (ASX:VBS) Stock Under Pressure: What Investors Should Know - Kalkine
googlenews · 27 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss VBS
Start a research thread or post the first pulse update